Nurix Therapeutics

NURIX THERAPEUTICS INC

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

APLD

BAOS

BINI

CARM

CCCX

CODI

FMFC

KIDS

LEVI

NRIX

ORBS

SGBX

SUGP

SWKH

TCRT

USNA

YHGJ

El premercado estadounidense se mueve con fuerza: descubre qué acciones suben más del 80 % y cuáles se desploman antes de la apertura.

Las acciones de Applied Digital (APLD) suben alrededor de un 25 %; Aquí están 20 acciones que se mueven en el premercado

Levi Strauss & Co

Earnings

Equities

Long Ideas

APOG

VNRX

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: APOG, LEVI, VNRX, USNA y NRIX.

5 acciones en el foco este viernes: APOG, LEVI, VNRX, USNA y NRIX

Nurix Therapeutics Inc

Press Releases

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

Health Care

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Absci

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

Akebia Therapeutics

Astria Therapeutics

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

CareDx

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Erasca

Geron

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gyre Therapeutics

I-MAB

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

MeiraGTx Hldgs

Myriad Genetics

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Rezolute

Tyra Biosciences

UroGen Pharma

Vir Biotechnology

Morgan Stanley

HC Wainwright & Co.

Piper Sandler

Oppenheimer

Comments

Nurix Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL